Clinical Study
Testing the Drug VE202 in Adults with Mild-to-Moderate Ulcerative Colitis
Mild-to-Moderate Ulcerative Colitis (UC) causes inflammation of the large intestine (colon). This study will test a drug called VE202 to treat adults with this disease. The study wants to see if the drug will help people with the disease and is safe. People in this study will be randomly chosen to be treated with the study drug VE202 or a placebo. The drug and placebo are taken as a swallowed pill. The placebo does not have the treatment. Later in the study, people on the placebo are switched to the drug, and people on the drug are switched to the placebo. Participation in the study requires up to 2.5 years. Medical tests will be done during the study to track the health of participants.
For more information contact:
Julie Will
julie.will@hsc.utah.edu
801-587-9060
IRB#: IRB_00168499
| PI: John Valentine
| Department: GASTROENTEROLOGY
| Approval Date: 2023-10-11 06:00:00
Specialties: Gastroenterology
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 18 to 75 years old
- Confirmed diagnosis of Ulcerative Colitis
- Active or moderate Ulcerative Colitis
- Willing to use specific birth control during study participation
- Attend in person at the study clinic
Exclusion Criteria:
- Pregnant or breastfeeding
- Active infection of the body
- Any other active chronic disease that affects participation
- History of drug or alcohol abuse
Will I be paid for my time?
Yes